Walgreens resolves $595M lawsuit over COVID testing

Walgreens has agreed to pay a telemedicine company $595 million to resolve a dispute over COVID-19 testing services.

Everly Health, at the time known as PWNHealth, claimed that Walgreens breached the terms of a 2020 agreement for its telehealth providers to conduct COVID-19 tests for the pharmacy chain. Specifically, Everly was tasked with fulfilling orders for tests issued through Walgreens’ website.

According to court documents, Walgreens allegedly began bringing services in-house, including test order fulfillment, which had been contracted to Everly. The telehealth provider claims this was done without its knowledge, despite Walgreens using its branding.

While Walgreens does not admit to violating its contractual obligations, the $595 million payout brings the conflict to an end. According to court documents, Walgreens agreed to send the money within two days of it being finalized by a judge.

Everly initially fought the pharmacy in arbitration that began in 2022, with Walgreens ultimately losing and being stuck with a $988 million tab. In an appeal to a Delaware court, Walgreens argued that the amount should be capped at $79 million, citing terms in the contract. Last week, the court upheld the initial arbitration ruling.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”